The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALTS | -71.08% | -81.92% | -28.97% | -99% |
| S&P | +14.43% | +77.25% | +12.13% | +1,583% |
JanOne, Inc. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.
No news articles found for Alt5 Sigma.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.58M | 53.3% |
| Gross Profit | $1.76M | 573.2% |
| Gross Margin | 23.19% | 17.9% |
| Market Cap | $327.13M | 1347.4% |
| Market Cap / Employee | $32.71M | 0.0% |
| Employees | 10 | 0.0% |
| Net Income | $46.65M | 5775.3% |
| EBITDA | -$15,641.00K | -1851.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.32M | -15.6% |
| Accounts Receivable | $28.54M | 31.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.76M | 19.7% |
| Short Term Debt | $9.05M | 128.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 4.01% | 38.1% |
| Return On Invested Capital | -54.32% | 18.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8,755.00K | -308.8% |
| Operating Free Cash Flow | -$8,739.00K | -308.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 17.71 | 19.81 | 29.39 | 6.34 | -6.04% |
| Price to Sales | 5.47 | 3.56 | 6.78 | 21.01 | 544.39% |
| Price to Tangible Book Value | -1.71 | -1.39 | -2.84 | -1.52 | 132.55% |
| Price to Free Cash Flow TTM | 6.98 | 38.61 | 82.55 | - | |
| Enterprise Value to EBITDA | -199.89 | -99.79 | -145.83 | -35.66 | -168.94% |
| Free Cash Flow Yield | 14.3% | 2.6% | 1.2% | - | |
| Return on Equity | -34.7% | -41.8% | -46.0% | 4.4% | -106.20% |
| Total Debt | $13.07M | $14.27M | $22.73M | $17.81M | 57.84% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
